Background and Purpose-Increased systolic blood pressure variability (BPV) is associated with worse outcome after acute ischemic stroke and may also have a negative impact after intracerebral hemorrhage. We sought to determine whether increased BPV was detrimental in the ATACH-2 (Antihypertensive Treatment of Acute Cerebral Hemorrhage II) trial. Methods-The primary outcome of our study was a 3-month follow-up modified Rankin Scale of 3 to 6, and the secondary outcome was a utility-weighted modified Rankin Scale. We calculated blood pressure mean and variability using systolic blood pressure from the acute period (2-24 hours postrandomization) and subacute period (days 2, 3, and 7). Results-The acute period included 913 patients and the subacute included 877. For 5 different statistical measures of systolic BPV, there was a consistent association between increased BPV and worse neurological outcome in both the acute and subacute periods. This association was not found for systolic blood pressure mean. Conclusions-In this secondary analysis of ATACH-2, we show that increased systolic BPV is associated with worse longterm neurological outcome. Additional research is needed to find techniques that allow early identification of patients with an expected elevation of BPV and to study pharmacological or protocol-based approaches to minimize BPV. (Stroke.
A cute intracerebral hemorrhage (ICH) is a major cause of death and disability with few effective treatment options. Hypertension is both a risk factor for ICH and predicts a worse outcome. 1 However, large clinical trials have not shown that aggressive blood pressure reduction after ICH lowers the rate of death or disability.
1,2 Increased systolic blood pressure variability (BPV) is associated with a higher risk of incident stroke, coronary artery disease, and poor outcome after ischemic stroke. 3, 4 Post hoc analyses of the INTERACT2 (Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial) and FAST-MAG (Field Administration of Stroke Therapy-Magnesium) indicated that increased BPV was harmful after ICH. 5, 6 We sought to determine whether increased BPV was detrimental in the ATACH-2 (Antihypertensive Treatment of Acute Cerebral Hemorrhage II) trial. 
Methods
This is a secondary analysis of ATACH-2, a randomized trial of patients with nontraumatic ICH to determine whether an intensive antihypertensive protocol (goal SBP of 110-139 mm Hg) was superior to a standard approach (goal SBP of 140-179 mm Hg). The anonymized ATACH-2 data set, received with a local Institutional Review Board waiver, is available through National Institute of Neurological Disorders and Stroke at https://www.ninds.nih.gov. We created an acute (2-24 hours postrandomization) and subacute period (days 2-7). In the acute period, the ATACH-2 trial recorded the highest and lowest SBP for every hour and, in the subacute period, the 2 highest and lowest SBP readings separated by 1 hour for day 2, 3, and 7. We censored blood pressure readings for hours 0 to 2 after randomization, when the study intervention caused a rapid decrease in blood pressure.
Our primary outcome was unfavorable neurological outcome, defined as a modified Rankin Scale (mRS) score of 3 to 6, measured 3 months after randomization. The secondary outcome was a utilityweighted mRS. 7 Additional outcome included change in ICH volume (ΔICH), midline shift (Δshift), and cerebral edema (Δedema). We calculated systolic mean and 5 measures of systolic BPV: SD, coefficient of variation, average real variability, successive variation, and residual SD. Blood pressure variables were analyzed both per 10 mm Hg shift and in quintiles. 4 We performed separate analyses for the acute and subacute time periods using logistic regression and used Spearman rank correlation to test for association between BPV and ΔICH, Δshift, and Δedema.
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Results
Of the 1000 patients enrolled in ATACH-2, our acute period included 913 and the subacute included 877 (Table 1 ). The censored patients had either no data on the primary outcome (n=39), incomplete blood pressure data (n=16 in the acute and n=58 in the subacute period), or incomplete clinical information (n=32 in the acute and n=26 in the subacute period). The 5 measures of systolic BPV, but not systolic mean, were consistently associated with the primary outcome in both time periods (Table 2 ). The SD was significantly higher for patients with the primary outcome (acute period=15.1±5.8 versus 13.7±4.4 mm Hg, P<0.001; subacute period=25.4±8.6 versus 21.1±7.8 mm Hg, P<0.001). This association was stronger in the subacute than the acute period, with tighter confidence intervals and larger effect sizes. Increased BPV was also associated with worse utility-weighted mRS in both time periods ( Figure; P trend <0.001). Our findings relating BPV to the primary and secondary outcomes remained significant after adding systolic mean as a covariable or after stratifying the cohort by intensive versus standard treatment arm and running regression models separately (data not shown).
In the acute period, there were 901 patients with a computed tomography before randomization and 24 hours later. In this group of patients, there were no significant associations or trends between the acute period BPV or mean and ΔICH, Δedema, or Δshift. For SD, the Spearman ρ was r=0 for ΔICH (P=0.944), r=0.02 for Δedema (P=0.560), and r=0.06 for Δshift (P=0.09).
Conclusions
In ATACH-2 patients, we find a consistent association between unfavorable neurological outcome and increased systolic BPV, which is also associated with worse utilityweighted mRS, an outcome measure with better weighting from the patient or caregiver perspective. Our findings are similar to the secondary analyses of INTERACT2 and FAST-MAG, 5, 6 with an important difference-we find a stronger association between increased BPV and worse outcome in the subacute period. The FAST-MAG analysis did not look at subacute blood pressure. The discrepancy between our findings and the INTERACT2 analysis may be because the trial interventions can reduce BPV and ATACH-2's only lasted 24 hours, whereas INTERACT2's continued for a full 7 days.
This study has several strengths compared with prior analyses, including considerably more blood pressure readings, which increase the precision of BPV, and a single first-line antihypertensive treatment (nicardipine). The main limitation is the methodology of blood pressure collection in ATACH-2, which introduced bias by recording the highest and lowest values. This increases BPV for all patients, but our results remain relevant because outliers are what is targeted in protocols to treat blood pressure. ATACH-2 also only enrolled patients with an SBP >180 after ICH onset and excluded patients with very severe ICH.
This study, and the similar results of the INTERACT2 and FAST-MAG analyses, should prompt clinicians to consider monitoring BPV after ICH and reinforce the need for additional research into reducing BPV after stroke. Potential therapeutic interventions include transitioning from the nicardipine used in ATACH-2 to an ultrashort-acting antihypertensive, which could be titrated rapidly to achieve steady blood pressure levels, or more intensive monitoring and titration protocol of blood pressure management for an extended period of time. Research is also needed to find techniques that allow early identification of patients with an expected elevation of BPV.
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